CB[7]-PEG Purification via Tangential Flow Filtration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale synthesis of Cucurbit[7]uril-PEG (CB[7]-PEG) conjugates are inefficient and costly, particularly due to the limitations of dialysis in removing copper catalysts and achieving rapid purification, which is essential for stabilizing insulin formulations and avoiding liver toxicity associated with covalent PEGylation.
Innovation Solution
The use of diafiltration, tangential flow filtration, column chromatography, affinity 'pull-down' techniques, and selective precipitation methods for purification, with the economical removal of copper catalysts using metal-chelating resins, to produce CB[7]-PEG on a commercial scale, ensuring stability and minimizing pharmacokinetic impact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dialysis is used for purification, then copper catalysts can be removed, but the process is inefficient and costly for large-scale production
Solution Approach 1:
The patent replaces the traditional dialysis mechanical system with tangential flow filtration (TFF) technology. TFF uses a membrane separation system with tangential flow configuration to achieve both copper catalyst removal and large-scale production efficiency simultaneously, eliminating the need for extensive dialysis steps while maintaining purification effectiveness
Solution Approach 2:
The patent changes the purification parameters by introducing controlled flow rates, pressure gradients, and membrane selectivity parameters in the TFF system. By optimizing these parameters, the process achieves rapid separation of CB[7]-PEG conjugates from copper catalysts and other impurities, dramatically improving production efficiency compared to conventional dialysis
2Stability of the object's composition
If covalent PEGylation is used to stabilize insulin, then protein stability is improved, but liver toxicity occurs and pharmacokinetics are extended
Solution Approach 1:
The patent extracts the harmful covalent bonding mechanism from the PEGylation process and replaces it with non-covalent host-guest binding using CB[7]-PEG conjugates. This extraction eliminates the liver toxicity associated with covalent PEGylated insulin while maintaining the stabilizing effect through reversible binding interactions
Solution Approach 2:
The patent introduces CB[7]-PEG as an intermediary excipient that mediates between the insulin protein and the PEG stabilization function. The CB[7] macrocycle binds non-covalently to insulin while the PEG chain provides stabilization, creating a beneficial intermediary complex that avoids the direct covalent modification and associated toxicity
3Speed
If rapid acting insulin formulation is developed, then pharmacokinetics are improved, but protein stability may be compromised
Solution Approach 1:
The patent segments the stabilization function from the pharmacokinetic control function. CB[7]-PEG provides protein stability through non-covalent binding, while the rapid pharmacokinetics are achieved through the rapid dissociation of the host-guest complex in the body. This segmentation allows both functions to be optimized independently
Solution Approach 2:
The patent employs dynamic non-covalent binding interactions that are stable in the formulation but rapid in the body. The host-guest binding between CB[7]-PEG and insulin is dynamic, allowing rapid dissociation upon dilution in the body, thus achieving rapid pharmacokinetics while maintaining formulation stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable efficient and cost-effective large-scale production of CB[7]-PEG, stabilizing insulin formulations by avoiding liver toxicity and maintaining rapid pharmacokinetics, while being applicable to other biopharmaceutical agents, thus providing a superior excipient for rapid acting insulins.
Implementation Method 1
it is economical to remove the copper catalyst component of the 'click' chemistry reaction mixture using a commercially available metal-chelating resin
Implementation Method 2
Methods of purification for the large scale synthesis of CB[7]-PEG may include at least one of diafiltration or tangential flow filtration
Implementation Method 3
column chromatography
Implementation Method 4
selective precipitation methods
Data Source
AI summary
Methods of purification for the large scale synthesis of CB[7]-PEG may include at least one of diafiltration or tangential flow filtration, column chromatography, affinity “pull-down” techniques, or selective precipitation methods. In one embodiment, the method includes providing a reaction mixture containing synthesized CB[7]-PEG, providing a membrane selected to be below the nominal molecular weight of CB[7]-PEG, and removing small molecular weight contaminant species from the reaction mixture using the membrane. In embodiments, regardless of which purification method is used, a copper catalyst component of the “click” chemistry reaction mixture may be removed using a commercially available metal-chelating resin.